<table>
<thead>
<tr>
<th>Type of Cancer</th>
<th>Open Immunotherapy Clinical Trials</th>
<th>You may be eligible if:</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung</strong> (Non-Small Cell Carcinoma)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Incyte BMS INCB24360-204</strong>&lt;br&gt;A Phase I/II Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of stage IIIIB or IV, or recurrent NSCLC&lt;br&gt;• Received only one prior systemic regimen and contained a platinum agent&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, SD</td>
</tr>
<tr>
<td></td>
<td><strong>CTSU S1400 (MAP)</strong>&lt;br&gt;Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of squamous cell lung carcinoma&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Received at least one line of platinum-based chemotherapy&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN</td>
</tr>
<tr>
<td></td>
<td><strong>ECOG-ACRIN E4512</strong>&lt;br&gt;A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</td>
<td>• 18 years or older&lt;br&gt;• Must have had complete surgical resection&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN</td>
</tr>
<tr>
<td></td>
<td><strong>Keynote 189</strong>&lt;br&gt;A Randomized, Double-Blind, Phase III Study of Platinum + Pemetrexed Chemotherapy With or Without Pembrolizumab [MK-3475] in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of stage IV non-squamous non-small cell lung carcinoma&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• No prior treatment for advanced/metastatic NSCLC&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND</td>
</tr>
<tr>
<td></td>
<td><strong>Alliance A151216</strong>&lt;br&gt;Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of stage IB-III NSCLC&lt;br&gt;• Must have complete resection&lt;br&gt;• Must have tissue available for EGFR/ALK testing&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN</td>
</tr>
<tr>
<td></td>
<td><strong>BMS CA209370 Checkmate 370</strong>&lt;br&gt;Master Protocol of Phase I/II Studies of Nivolumab in Advanced NSCLC using Nivolumab as maintenance after Induction Chemotherapy or as first-line Treatment Alone or in Combination with Standard of Care Therapies (CA209370)</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of stage IV squamous or non-squamous NSCLC&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Bismarck, ND</td>
</tr>
<tr>
<td><strong>Head and Neck</strong> (Squamous Cell Carcinoma)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>CheckMate 358</strong>&lt;br&gt;Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase I/II Study of Nivolumab [BMS-936558] in Subjects with Virus-Positive and Virus-Negative Solid Tumors</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of HNSCC&lt;br&gt;• Are eligible for surgical resection or have progressive metastatic/recurrent disease&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD</td>
</tr>
<tr>
<td></td>
<td><strong>SH MISP203</strong>&lt;br&gt;Phase IB Study of Pembrolizumab in Combination with Chemo Radiotherapy (CRT) for Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of HNSCC&lt;br&gt;• Are eligible for curative intent treatment&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND Bismarck, ND</td>
</tr>
<tr>
<td></td>
<td><strong>Keynote 048</strong>&lt;br&gt;Phase III Clinical Trial of Pembrolizumab in First Line Treatment of Recurrent/Metastatic HNSCC</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of HNSCC&lt;br&gt;• Not receiving any other treatment&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND</td>
</tr>
<tr>
<td></td>
<td><strong>Incyte BMS INCB24360-204</strong>&lt;br&gt;A Phase I/II Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of metastatic or recurrent squamous cell carcinoma&lt;br&gt;• Received no more than two prior systemic regimens for advanced disease&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND</td>
</tr>
<tr>
<td><strong>Colorectal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Keynote 177</strong>&lt;br&gt;Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of colorectal carcinoma&lt;br&gt;• Has not received prior systemic treatment for stage IV colorectal cancer&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD</td>
</tr>
<tr>
<td>Type of Cancer</td>
<td>Open Immunotherapy Clinical Trials</td>
<td>You may be eligible if:</td>
<td>Location</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
</tbody>
</table>
| **Gastric or Gastroesophageal**   | **Keynote 180** A Phase II Study of Pembrolizumab Monotherapy in third-line previously treated subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus | • 18 years or older  
• Diagnosis of gastroesophageal adenocarcinoma or squamous cell carcinoma  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD |
|                                  | **Keynote 181** A randomized open-label phase III study of single agent pembrolizumab vs. physician's choice of single agent paclitaxel or docetaxel in subjects with advanced/metastatic squamous cell cancer and adenocarcinomas of the esophagus that have progressed after first-line standard therapy | • 18 years or older  
• Diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagus  
• Disease that can be measured on a CT scan  
• Previously treated with first-line standard therapy  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |
| **Gynecologic Cancer**            | **CheckMate 358** (Cervical) Non-comparative, two-cohort, single-arm, open-label, phase II/II study of nivolumab (BMS-936558) in subjects with virus-positive and virus-negative solid tumors | • 18 years or older  
• Diagnosis of stage II to IVa disease  
• Are eligible for planned surgery or chemotherapy/radiation therapy  
• Otherwise healthy | Sioux Falls, SD |
| **Prostate**                      | **Keynote 199** Phase II trial of pembrolizumab (MK-3475) in subjects with metastatic castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy | • 18 years or older  
• Diagnosis of prostate cancer  
• Has received chemotherapy and endocrine therapy for their cancer  
• Disease that can be measured on a CT scan or disease that is considered non-measurable  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |
| **Melanoma**                      | **CTSU S1404** A phase III randomized trial comparing physician/patient choice of high dose interferon or ipilimumab to MK-3475 (pembrolizumab) in patients with high risk resected melanoma | • 18 years or older  
• Diagnosis of stage III or IV melanoma that has been completely removed  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
|                                  | **ECOG-ACRIN E6134** A randomized phase III trial of dabrafenib + trametinib followed by ipilimumab + nivolumab at progression versus ipilimumab + nivolumab followed by dabrafenib + trametinib in patients with advanced BRAFV600 mutant melanoma | • 18 years or older  
• Diagnosis of unresectable stage III or IV melanoma  
• Disease that can be measured by CT scan  
• Must have BRAF v600E or BRAF v600K mutations  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
|                                  | **ECOG-ACRIN E6141** Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or IV melanoma | • 18 years or older  
• Diagnosis of unresectable stage III or IV melanoma  
• Disease that can be measured by CT scan  
• Must have known BRAF mutational status (wild-type or mutated)  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
|                                  | **Incyte BMS INCB24360-204** A phase I/II study of the safety, tolerability, and efficacy of INCB24360 administered in combination with nivolumab in select advanced cancers | • 18 years or older  
• Diagnosis of unresectable or stage IV melanoma  
• Must have known BRAF mutational status of V600E  
• Have received no treatment or only one prior systemic treatment  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |
| **Breast**                        | **Keynote 119** A randomized open-label phase III study of single agent pembrolizumab versus single agent chemotherapy per physician's choice for metastatic triple negative breast cancer (mTNBC) | • 18 years or older  
• Have received one or two prior systemic treatments for metastatic breast cancer  
• Diagnosis of triple negative breast cancer  
• Disease that can be measured by CT scan  
• Otherwise healthy | Sioux Falls, SD |
| **Merkel Cell Skin Cancer**       | **CheckMate 358** Non-comparative, two-cohort, single-arm, open-label, phase II/II study of nivolumab (BMS-936558) in subjects with virus-positive and virus-negative solid tumors | • 18 years or older  
• Eligible for neo-adjuvant treatment  
• Otherwise healthy | Sioux Falls, SD |
| **Non-Hodgkin Lymphomas**         | **Incyte BMS INCB24360-204** A phase I/II study of the safety, tolerability, and efficacy of INCB24360 administered in combination with nivolumab in select advanced cancers | • 18 years or older  
• Diagnosis of relapsed or refractory DLBCL  
• Not a candidate for curative therapy or hematopoietic stem cell transplantation  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |